Horizon Discovery Group plc (LSE: HZD) ("Horizon" or “the Group”), a global leader in the application of gene editing and gene modulation technologies, has announced that it has signed a collaboration and license agreement with Mammoth Biosciences (“Mammoth” or the “Company”), to access Mammoth’s novel CRISPR platform and thereby facilitate delivery of a new generation of genetically engineered CHO cells for the production of biotherapeutics such as therapeutic antibodies.
Horizon’s Bioproduction business unit currently offers the biopharmaceutical industry a well characterized CHO cell line and customized services to facilitate the development and identification of best performing gene-edited cell lines. Since entering this market five years ago, the business unit has generated significant sales revenues, secured more than 60 licensing engagements, and seen customers succeed with at least five Investigational New Drug (IND) filings. This agreement supports the Company’s strategy to focus on its core high growth markets, while continuing to ...
